[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571927":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"University of Florida","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Adult Cohort; n=100 (50 Hispanic American adults and 50 non-Hispanic American adults)",null,"The participants in this PASOS pilot will include 50 self-identified HA individuals and 50 self-identified non-HA individuals between the ages of 55-85 years, with no psychometric evidence of neuropsychological decline. We plan to enroll an equal number of women and men. Race and ethnicity in this study will be determined via self-report or self-identification by participants.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Stacey Alvarez-Alvarado, PhD, MS","CONTACT","904-244-9937","salvarezalvarado@ufl.edu",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"University of Florida, College of Medicine-Jacksonville","RECRUITING","Jacksonville","Florida","32206","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-81.65565,30.33218,{"lat":31,"lon":30},[34,36],{"name":35,"role":15,"phone":16,"phoneExt":10,"email":17},"Stacey Alvarez-Alvarado",{"name":37,"role":15,"phone":38,"phoneExt":10,"email":39},"Sol Colindres Solorzano Research Coordinator","9042449711","Geminis.ColindresSolorzano@jax.ufl.edu",{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571927","physical-and-cognitive-aging-study-in-older-adults-100571927",false,"NCT06726616","Physical and Cognitive Aging Study in Older Adults","PASOS: Physical and Cognitive Aging Study in Older Adults","PASOS","Inclusion Criteria:\n\n• Hispanic and non-Hispanic adults age 55-85 years, at least 8th grade education, community dwelling.\n\nAdditional Inclusion for Hispanic Americans\n\n* Self-identify as Hispanic American\n* Report Spanish as primary language • No evidence of dementia or mild cognitive impairment based on cognitive screening \\[i.e., Montreal Cognitive Assessment (MoCA) administered during Visit 1; ≥26 among non-Hispanic White, ≥25 among Hispanics, ≥24 among non-Hispanic Blacks (Milani et al., 2018)\\]\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Artificial joint or severe disability that would make it impossible or contraindicated performing the isokinetic test\n* Sensory loss (vision, hearing) or motor deficits that would preclude participation in the experimental tasks or neuropsychological assessment\n* Previous major strokes or other known significant brain abnormalities or diseases affecting the brain and\u002For cognition (e.g., Parkinson disease, multiple sclerosis, seizure disorder, brain surgery, moderate TBI, REM Behavior Sleep Disorder, untreated sleep apnea, etc.)\n* Unstable and uncontrolled medical conditions (metastatic cancer, HIV, moderate-severe kidney disease, uncontrolled diabetes, uncontrolled hypertension, severe cardiac disease, etc.). No current cancer diagnosis.\n* Current or past history of major psychiatric disturbance including schizophrenia, or active psychosis, bipolar disorder, current major depressive episode, current alcohol or substance abuse or history thereof within the past six months\n* Use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory)\n* Use of prescribed 'memory enhancing' medications, such as Aricept or Namenda\n* Previous participation in a cognitive or physical activity training study within the last 6 months or current involvement in another study involving cognitive, physical or other intervention at the time of enrollment",true,"ALL","55 Years","85 Years",{"count":55,"type":56},100,"ESTIMATED","12 Months","OBSERVATIONAL","Hispanic Americans are the fastest growing older adult group in the United States, disproportionally increasing the risk of an Alzheimer's disease and related dementias diagnosis. Efforts to reduce this risk and mitigate the related cognitive\u002Fphysical declines are critical. The aim of this study is to assess the feasibility of enrolling older adults into an aging trajectory cohort, while generating preliminary data on associations of physical and cognitive aging trajectories. Our secondary objective is to generate preliminary data on the association of standard measures of physical activity and physical function with cognitive status. This study fits within our longitudinal research goal to reduce dementia incidence by understanding the mechanisms that drive the cognitive-physical aging trajectory.",[61,62,63,64,65],"Older Adults (65 Years and Older)","Hispanic Americans","Cognitive Aging","Aging, Healthy","Exercise","2026-06-03",{"date":68,"type":69},"2026-06-04","ACTUAL",{"date":71,"type":69},"2025-03-19",{"date":73,"type":56},"2027-09-20",{"name":5,"class":6},1]